GINOLIS OY

Their core work

Ginolis is a Finnish precision technology SME specializing in automated assembly and manufacturing of diagnostic devices and biosensor platforms. Their core capability lies in translating advanced detection physics — plasmonic sensing, microfluidics, pyroelectric transduction — into manufacturable, high-throughput diagnostic instruments. In EU research projects, they serve as the industrialization bridge between laboratory science and deployable medical diagnostics, contributing device integration expertise that academic partners typically lack. Their work spans ultra-sensitive detection of disease biomarkers, from early-stage cancer markers to Alzheimer's plasma diagnostics.

What they specialise in

How they've shifted over time

In their first H2020 project (2015–2018), Ginolis contributed to plasmonic device development for cancer detection — an application-specific focus with no recorded keyword fingerprint, suggesting a narrower, more component-level role. By their second project (2019–2022), a richer keyword profile emerged: biosensors, microfluidics, photonics, nano-optics, immunoassay, pyroelectric effect — indicating they took on a broader, more technically visible role integrating multiple detection modalities. The trajectory suggests Ginolis is moving from single-technology contributor toward multi-modal diagnostic platform integrator.

Ginolis is expanding from single optical-detection applications toward integrated multi-physics biosensor platforms, making them an increasingly valuable partner for consortia developing next-generation point-of-care or laboratory diagnostics.

How they like to work

Ginolis participates exclusively as a consortium partner — they have never coordinated an H2020 project — which is consistent with a technology SME that contributes specialized manufacturing or device integration capability rather than leading scientific programs. With 22 unique partners across 9 countries in just two projects, they operate in large, international research consortia rather than tight bilateral arrangements. This breadth of contacts relative to project count suggests they are well-networked and actively sought out for their industrial role in otherwise academically-led teams.

Ginolis has built a network of 22 unique consortium partners across 9 countries through just two projects, suggesting they participate in large, multi-partner consortia typical of RIA calls. Their geographic spread across Europe reflects the international composition of health-technology research programs rather than a deliberate regional focus.

What sets them apart

Ginolis occupies a rare niche as a Finnish industrial SME that can bridge advanced biosensor physics — photonics, microfluidics, pyroelectric transduction — with scalable device manufacturing, a combination that pure research groups and large industrial players both struggle to offer. For consortium builders, they provide the "valley of death" crossing capability: taking a laboratory detection concept and making it manufacturable. Their consistent participation in high-sensitivity diagnostics (cancer, Alzheimer's) signals domain credibility that generic contract manufacturers cannot match.

Highlights from their portfolio

• SensApp
  Highest-funded project (€498,750) with the richest technical scope — integrating biosensors, microfluidics, photonics, and pyroelectric detection for plasma-based Alzheimer's diagnosis, placing Ginolis at the intersection of multiple advanced detection technologies.
• ULTRAPLACAD
  Ginolis's entry into H2020 collaborative research, targeting ultra-sensitive plasmonic cancer diagnostics — an early signal of their strategic bet on precision medical diagnostics as a core market.